{"146501":{"#nid":"146501","#data":{"type":"event","title":"Prof. Babu Tekwani, University of Mississippi","body":[{"value":"\u003Cp\u003EProf. Babu Tekwani, University of Mississippi\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EChiral Switches for New Drug Discovery: Optimization of Pharmacologic \u0026amp; Safety Profiles\u003C\/em\u003E\u003C\/p\u003E\u003Cp\u003EBiochemistry Division Seminar Series\u003C\/p\u003E\u003Cp\u003EThe effect of isomerism on biological activity and toxicity of drugs is well documented.\u0026nbsp;Enantioselectivity is an important feature of the living world. Chiral centers are common in biomolecules, which are made up of units that have the same sense of chirality. Essential physiological processes are homochiral. They typically show 100% stereoselectivity and involve only one of the possible enantiomers. When exogenous compounds including therapeutics are introduced into the body, biological targets show a high degree of \u003Cstrong\u003Echiral discrimination.\u003C\/strong\u003E Effects of different enantiomers are often markedly different. Differential interaction of enantiomers with chiral targets, such as receptors, enzymes, transporters and other biomolecules and enantioselective ADME-PK\/PD profiles form the molecular basis for this enantioselectivity. \u003Cem\u003EDe novo\u003C\/em\u003E development of a drug in enantiomerically pure form, and \u201cswitch\u201d from an existing racemic drug to one of its isomers are now common approaches in drug development. FDA recommends evaluation of both enantiomers as well as racemic mixtures of a chiral drug before its introduction into the clinic. From any perspective \u2013 regulatory, scientific, and humanitarian \u2013 use of a chiral drug in racemic form is not acceptable. In several cases, chiral switches have allowed remarkable improvements in therapeutic profile of current drugs. The chiral switches are also being exploited to allow line of extension of blockbuster drugs. While we can empirically determine which enantiomer has a better safety to efficacy profile, it is important to understand the molecular bases of these advantages, and to rationally apply them to optimize pharmacologic \u0026amp; safety profiles of drugs.\u003C\/p\u003E\u003Cp\u003EFor more information contact \u003Ca href=\u0022mailto:aoyelere@gatech.edu\u0022\u003EProf. Adegboyega Oyelere\u003C\/a\u003E (404-894-4047).\u003C\/p\u003E","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EProf. Babu Tekwani, University of Mississippi\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EChiral Switches for New Drug Discovery: Optimization of Pharmacologic \u0026amp; Safety Profiles\u003C\/em\u003E\u003C\/p\u003E\u003Cp\u003EBiochemistry Division Seminar Series\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"Prof. Babu Tekwani, University of Mississippi"}],"uid":"27275","created_gmt":"2012-08-15 16:17:14","changed_gmt":"2016-10-08 01:59:28","author":"Shirley Tomes","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2012-08-28T17:00:00-04:00","event_time_end":"2012-08-28T18:00:00-04:00","event_time_end_last":"2012-08-28T18:00:00-04:00","gmt_time_start":"2012-08-28 21:00:00","gmt_time_end":"2012-08-28 22:00:00","gmt_time_end_last":"2012-08-28 22:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"related_links":[{"url":"http:\/\/www.pharmacy.olemiss.edu\/php\/sopquery3.php?id=71","title":"Prof. Babu Tekwani"}],"groups":[{"id":"85951","name":"School of Chemistry and Biochemistry"}],"categories":[],"keywords":[],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1795","name":"Seminar\/Lecture\/Colloquium"}],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003EShirley Tomes (404-894-0591) \u003Ca href=\u0022mailto:shirley.tomes@chemistry.gatech.edu\u0022\u003Eshirley.tomes@chemistry.gatech.edu\u003C\/a\u003E\u003C\/p\u003E","format":"limited_html"}],"email":[],"slides":[],"orientation":[],"userdata":""}}}